MindBio Therapeutics (CSE: MBIO; OTCQB: MBIOF) is a clinical-stage company developing MB22001, a titratable, take-home microdose formulation of LSD designed for at-home use. Its lead program targets major depressive disorder, and the company has run Phase 2a and Phase 2b microdosing trials — reporting Phase 2b topline results in late 2025 — while also exploring microdosing for indications such as sleep and end-of-life distress. MindBio has run one of the largest controlled microdosing programs in the sector to date.
MindBio Therapeutics News 37 articles
- MindBio's Phase 2b take-home LSD microdosing trial underperforms placebo in major depression
- MindBio Issues Restricted Stock Units
- MindBio Therapeutics Corp. Announces Private Placement and Debt Settlements
- MindBio Issues Warrants to Haywood Securities
- MindBio Adopts New Equity Incentive Plan
- MindBio Acquires Life AI Corp. Pty. Ltd.
- Mindbio Announces Successful Outcome of Mandatory Independent Safety Audit in Phase 2b Clinical Trials
- Mindbio Announces Major Diagnostic Speech Discovery
- Mindbio Provides Update on Multiple Phase 2B Clinical Trials and Technological Developments
- MindBio Announces Arrangements to Address Mailing Delays Resulting from Canada Post Strike
- MindBio Announces Completion of Private Placement and Issuance of Listed Securities
- MindBio Reports a 72% Reduction in Severity of Depression Sustained Six Months After Treatment in Clinical Trials
- Mindbio Announces Clinical Trial Milestone In Phase 2B Microdosing Trials Targeting Existential Distress, Depression & Anxiety In Advanced Stage Cancer
- Mindbio Completes Final Post Treatment Milestone in Phase 2A Microdosing Depression Clinical Trial
- MindBio Announces Proposed Issuance of Listed Securities
- MindBio Develops Long Term Shelf-Stable Microdosing Formulation and is Progressing in Multiple Phase 2B Clinical Trials
- MindBio Therapeutics Enrolls 25th Participant into Landmark Take-Home Microdosing Depression Trial
- MindBio CEO Provides Video Update to Shareholders on Progress of World First, Government Approved Microdosing Clinical Trials
- MindBio Therapeutics Corp. Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials
- MindBio Reports Promising Phase 2A Results for Depression Treatment with LSD
- MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory
- Mindbio Therapeutics CEO Issues Letter To Shareholders
- MindBio Therapeutics Corp. Reports Durability Data from Phase 2A Clinical Trials in Depressed Patients Testing MB22001
- Mindbio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial
- Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
- MindBio Therapeutics Scientists Present Landmark Women’s Health Trials, Company to Release Phase 2A Depression Trial Secondary Data This Month
- MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
- MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry
- MindBio Therapeutics Corp. Begins Phase 2B Take-Home Microdosing Clinical Trial in Patients with Major Depressive Disorder
- MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomized Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder
- MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial
- MindBio Therapeutics Corp. Announces Completion of Landmark Phase 2A LSD Microdosing Clinical Trial in Distressive Disorder
- MindBio Therapeutics Corp. Begins Selection of Participants for its Phase 2 Randomized Double-Blind and Placebo Controlled Clinical Trial in Advanced Stage Cancer Patients Using Microdoses of Lylergic Acid Diethylamide and Meaning Centred Psychotherapy
- MindBio Therapeutics Corp. Announces Major Genetic Discovery in Microdosing Research
- MindBio Therapeutics Corp. Begins Dosing Mb22001 in Phase 2 Clinical Trial in World’s First Take-Home Microdosing Study in Patients with Depression
- Blackhawk and Mindbio Therapeutics Corp. (formerly, 1286409 B.C. LTD.) Announce Completion of Plan of Arrangement
- Blackhawk’s MindBio Therapeutics Announces Reveal Date for Presentation of Phase 1 Clinical Trial Data